<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Malignant <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are a heterogenous group of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, belonging to the 10 most frequent types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> worldwide </plain></SENT>
<SENT sid="1" pm="."><plain>In indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo> only patients with limited stage I/II (Ann Arbor) can be potentially cured by local irradiation </plain></SENT>
<SENT sid="2" pm="."><plain>However, about 85% of cases present with advanced stage; for these patients no established therapeutic strategy with curative potential exist </plain></SENT>
<SENT sid="3" pm="."><plain>The development of the anti-CD20 monoclonal antibody rituximab has been one of the major contributions in the field of anti-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> treatment in the recent years </plain></SENT>
<SENT sid="4" pm="."><plain>Various clinical trials have suggested the combination of chemotherapy and rituximab to be highly effective in de novo as well as relapsed indolent <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>